MX368070B - Derivado de carboximetil piperidina. - Google Patents
Derivado de carboximetil piperidina.Info
- Publication number
- MX368070B MX368070B MX2016006004A MX2016006004A MX368070B MX 368070 B MX368070 B MX 368070B MX 2016006004 A MX2016006004 A MX 2016006004A MX 2016006004 A MX2016006004 A MX 2016006004A MX 368070 B MX368070 B MX 368070B
- Authority
- MX
- Mexico
- Prior art keywords
- ring
- piperidine derivative
- formula
- present
- carboxymethyl piperidine
- Prior art date
Links
- VRDBIJCCXDEZJN-UHFFFAOYSA-N 2-piperidin-1-ylacetic acid Chemical class OC(=O)CN1CCCCC1 VRDBIJCCXDEZJN-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 abstract 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 abstract 1
- 229960001372 aprepitant Drugs 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un nuevo compuesto, el cual tiene actividad antagonista de receptor NK1, cuya actividad inhibidora de CYP3A4 es reducida comparada con aprepitant, y el cual es útil para la prevención o tratamiento de náusea y vómito inducido por quimioterapia de cáncer. Esto es, la presente invención se refiere a derivados de carboximetil piperidina representados por la siguiente fórmula (I) o una sal farmacéuticamente aceptable del mismo. En donde, el anillo A es un anillo de benceno o similares; el anillo B es un anillo de piridina o similares; R1 es C1-6 alquilo o C1-6 alcoxi; R2 y R3 son un átomo de hidrógeno o metilo; y n es un número entero de 0 a 5. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013231773 | 2013-11-08 | ||
| PCT/JP2014/079384 WO2015068744A1 (ja) | 2013-11-08 | 2014-11-06 | カルボキシメチルピペリジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006004A MX2016006004A (es) | 2016-08-12 |
| MX368070B true MX368070B (es) | 2019-09-18 |
Family
ID=53041521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006004A MX368070B (es) | 2013-11-08 | 2014-11-06 | Derivado de carboximetil piperidina. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10100030B2 (es) |
| EP (1) | EP3067349B1 (es) |
| JP (1) | JP5806420B1 (es) |
| KR (1) | KR20160078997A (es) |
| CN (1) | CN105745198B (es) |
| AU (1) | AU2014347644B2 (es) |
| BR (1) | BR112016009811A2 (es) |
| CA (1) | CA2930008A1 (es) |
| ES (1) | ES2671418T3 (es) |
| IL (1) | IL245286B (es) |
| MX (1) | MX368070B (es) |
| PL (1) | PL3067349T3 (es) |
| RU (1) | RU2673084C2 (es) |
| TW (1) | TWI657082B (es) |
| WO (1) | WO2015068744A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI649307B (zh) * | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| ES2813596T3 (es) * | 2015-12-07 | 2021-03-24 | Kissei Pharmaceutical | Antagonista del receptor NK1 |
| JP6432814B2 (ja) | 2016-06-21 | 2018-12-05 | Dic株式会社 | アルコール変性ポリアミドイミド樹脂およびその製造方法 |
| CN118496152A (zh) | 2019-11-15 | 2024-08-16 | 康堤医疗有限公司 | 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| CA2364662C (en) | 1999-02-24 | 2009-10-20 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| SI1103545T1 (en) | 1999-11-29 | 2004-02-29 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| HU230316B1 (hu) | 2000-07-14 | 2016-01-28 | F. Hoffmann-La Roche Ag | N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| CA2444395C (en) | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| DE602004008631T2 (de) | 2003-07-03 | 2008-07-10 | F. Hoffmann-La Roche Ag | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie |
| US20060030600A1 (en) | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| PL1863767T3 (pl) | 2005-03-23 | 2009-08-31 | Helsinn Healthcare Sa | Metabolity antagonistów NK-1 do leczenia wymiotów |
| WO2007028654A1 (en) | 2005-09-09 | 2007-03-15 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
| EP1928427B1 (en) | 2005-09-23 | 2009-12-30 | F.Hoffmann-La Roche Ag | Novel dosage formulation |
| AR060403A1 (es) * | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| BRPI0716069A2 (pt) | 2006-08-07 | 2013-09-17 | Albany Molecular Res Inc | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
-
2014
- 2014-11-06 KR KR1020167013135A patent/KR20160078997A/ko active IP Right Grant
- 2014-11-06 US US15/034,808 patent/US10100030B2/en not_active Expired - Fee Related
- 2014-11-06 RU RU2016122464A patent/RU2673084C2/ru not_active IP Right Cessation
- 2014-11-06 ES ES14860761.7T patent/ES2671418T3/es active Active
- 2014-11-06 CA CA2930008A patent/CA2930008A1/en not_active Abandoned
- 2014-11-06 AU AU2014347644A patent/AU2014347644B2/en not_active Ceased
- 2014-11-06 PL PL14860761T patent/PL3067349T3/pl unknown
- 2014-11-06 MX MX2016006004A patent/MX368070B/es active IP Right Grant
- 2014-11-06 TW TW103138516A patent/TWI657082B/zh not_active IP Right Cessation
- 2014-11-06 BR BR112016009811A patent/BR112016009811A2/pt not_active IP Right Cessation
- 2014-11-06 EP EP14860761.7A patent/EP3067349B1/en not_active Not-in-force
- 2014-11-06 JP JP2014555442A patent/JP5806420B1/ja not_active Expired - Fee Related
- 2014-11-06 CN CN201480060999.7A patent/CN105745198B/zh not_active Expired - Fee Related
- 2014-11-06 WO PCT/JP2014/079384 patent/WO2015068744A1/ja active Application Filing
-
2016
- 2016-04-21 IL IL245286A patent/IL245286B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015068744A1 (ja) | 2015-05-14 |
| BR112016009811A2 (pt) | 2017-12-05 |
| MX2016006004A (es) | 2016-08-12 |
| ES2671418T3 (es) | 2018-06-06 |
| US20160289206A1 (en) | 2016-10-06 |
| US10100030B2 (en) | 2018-10-16 |
| PL3067349T3 (pl) | 2018-06-29 |
| JP5806420B1 (ja) | 2015-11-10 |
| RU2016122464A3 (es) | 2018-06-25 |
| CA2930008A1 (en) | 2015-05-14 |
| CN105745198A (zh) | 2016-07-06 |
| CN105745198B (zh) | 2018-09-21 |
| AU2014347644A1 (en) | 2016-05-19 |
| RU2673084C2 (ru) | 2018-11-22 |
| EP3067349B1 (en) | 2018-02-28 |
| TW201605823A (zh) | 2016-02-16 |
| RU2016122464A (ru) | 2017-12-11 |
| IL245286A0 (en) | 2016-06-30 |
| EP3067349A1 (en) | 2016-09-14 |
| KR20160078997A (ko) | 2016-07-05 |
| AU2014347644B2 (en) | 2018-06-14 |
| TWI657082B (zh) | 2019-04-21 |
| JPWO2015068744A1 (ja) | 2017-03-09 |
| EP3067349A4 (en) | 2016-12-28 |
| IL245286B (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500553A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| NZ752732A (en) | Oxysterols and methods of use thereof | |
| CA2875877C (en) | Syk inhibitors | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| MX2016006004A (es) | Derivado de carboximetil piperidina. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| PH12016502358B1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MX2017013678A (es) | Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende. | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| PH12018502012A1 (en) | Griseofulvin compound | |
| PH12020500292A1 (en) | Pyridine compound substituted with azole | |
| MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). | |
| PH12014502663B1 (en) | Aromatic heterocyclic derivative and pharmaceutical | |
| EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
| BR112016025984A2 (pt) | derivado de ciclo-hexil piridina | |
| TW201613933A (en) | Long acting HIV protease inhibitor | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| IN2012DN01251A (es) | ||
| MY162945A (en) | Azole derivative | |
| MY176508A (en) | Anti-enterovirus 71 thiadiazolidine derivative | |
| MX355654B (es) | Derivado de paroxetina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |